Role of alpha-fetoprotein in selection of patients with hepatocellular carcinoma waiting for liver transplantation: Must we reconsider it?

International Journal of Biological Markers

Volumn 26, Issue 3, 2011, Pages 153-159

  Lai, Quirino ^a   Avolio, Alfonso W ^b   Manzia, Tommaso M ^c   Agnes, Salvatore ^b   Tisone, Giuseppe ^c   Berloco, Pasquale B ^a   Rossi, Massimo ^a  

^a POLICLINICO UMBERTO I   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Bridge therapies; Milan criteria; Recurrence

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PREDICTION; PREDICTOR VARIABLE; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT INDICATION; BLOOD; COHORT ANALYSIS; MIDDLE AGED; PROCEDURES;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 80053342674     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8557     Document Type: Article

References (24)

1. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
2. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080-6.
3. Rossi M, Merli M, Lai Q, et al. Outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Transpl Proc 2007; 39: 1895-7.
4. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-403.
5. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004; 239: 150-9.
6. Kwon CH, Kim DJ, Han YS, et al. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis 2007; 25: 313-9.
7. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85: 1726-32.
8. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology 2009; 49: 832-8.
9. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
10. Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688-701.
11. Bruix J, Sherman M, Llovet JM, et al. Clinical management on hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421-30.
12. Varela M, Forner A, Bruix J. Diagnosis and staging of hepatocellular carcinoma prior to transplantation: expertise or failure. Liver Transpl 2007; 12: 1445-7.
13. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-36.
14. Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-78.
15. McHugh PP, Gilbert J, Vera S, Koch A, Ranjan D, Gedaly R. Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. HPB (Oxford) 2010; 12: 56-61.
16. Duvoux C, Decaens T, Pessione F, et al. Pre-transplant AFP level is a simple and useful test for a controlled expansion of Milan criteria in liver transplant candidates for hepatocellular carcinoma. J Hepatol 2010; 52 (Suppl 1): S51-2.
17. Yang SH, Suh KS, Lee HW, et al. A revised scoring system utilizing serum alpha-fetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery 2007; 141: 598-609.
18. Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-37.
19. Cucchetti A, Piscaglia F, D'Errico Grigioni A, et al. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol 2010; 52: 880-8.
20. Del Gaudio M, Grazi GL, Principe A, et al. Influence of prognostic factors on the outcome of liver transplantation for hepatocellular carcinoma on cirrhosis: a univariate and multivariate analysis. Hepatogastroenterol 2004; 51: 510-4.
21. Cillo U, Navaglia F, Vitale A, et al. Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. Clin Chim Acta 2004; 347: 129-38.
22. Cillo U, Vitale A, Navaglia F, et al. Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World J Gastroenterol 2005; 11: 6920-5.
23. Xu X, Ke QH, Shao ZX, et al. The value of serum alpha- fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci 2009; 54: 385-8.
24. De Carlis L, Giacomoni A, Pirotta V, et al. Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surg 2003; 196: 887-97.